Dna antibody constructs and method of using same

Patent metadata

Field	Value
Publication number	US-2018346554-A1
Application number	US-201816005997-A
Country	US
Kind code	A1
Filing date	Jun 12, 2018
Priority date	Dec 13, 2012
Publication date	Dec 6, 2018
Grant date	—

Abstract

Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating disease in a subject using said composition and method of generation.

First claim

1 . A method of generating a synthetic antibody in a subject, the method comprising administering to the subject a composition comprising a recombinant nucleic acid sequence encoding an antibody or fragment thereof, wherein the recombinant nucleic acid sequence is expressed in the subject to generate the synthetic antibody.

2 . The method of claim 1 , wherein the antibody comprises a heavy chain polypeptide, or fragment thereof, and a light chain polypeptide, or fragment thereof.

3 . The method of claim 2 , wherein the heavy chain polypeptide, or fragment thereof, is encoded by a first nucleic acid sequence and the light chain polypeptide, or fragment thereof, is encoded by a second nucleic acid sequence.

4 . The method of claim 3 , wherein the recombinant nucleic acid sequence comprises the first nucleic acid sequence and the second nucleic acid sequence.

5 . The method of claim 4 , wherein the recombinant nucleic acid sequence further comprises a promoter for expressing the first nucleic acid sequence and the second nucleic acid sequence as a single transcript in the subject.

6 . The method of claim 5 , wherein the promoter is a cytomegalovirus (CMV) promoter.

7 . The method of claim 5 , wherein the recombinant nucleic acid sequence further comprises a third nucleic acid sequence encoding a protease cleavage site, wherein the third nucleic acid sequence is located between the first nucleic acid sequence and second nucleic acid sequence.

8 . The method of claim 7 , wherein the protease of the subject recognizes and cleaves the protease cleavage site.

9 . The method of claim 8 , wherein the recombinant nucleic acid sequence is expressed in the subject to generate an antibody polypeptide sequence, wherein the antibody polypeptide sequence comprises the heavy chain polypeptide, or fragment thereof, the protease cleavage site, and the light chain polypeptide, or fragment thereof, wherein the protease produced by the subject recognizes and cleaves the protease cleavage site of the antibody polypeptide sequence thereby generating a cleaved heavy chain polypeptide and a cleaved light chain polypeptide, wherein the synthetic antibody is generated by the cleaved heavy chain polypeptide and the cleaved light chain polypeptide.

10 . The method of claim 4 , wherein the recombinant nucleic acid sequence comprises a first promoter for expressing the first nucleic acid sequence as a first transcript and a second promoter for expressing the second nucleic acid sequence as a second transcript, wherein the first transcript is translated to a first polypeptide and the second transcript is translated into a second polypeptide, wherein the synthetic antibody is generated by the first and second polypeptide.

11 . The method of claim 10 , wherein the first promoter and the second promoter are the same.

12 . The method of claim 11 , wherein the promoter is a cytomegalovirus (CMV) promoter.

13 . The method of claim 2 , wherein the heavy chain polypeptide comprises a variable heavy region and a constant heavy region 1.

14 . The method of claim 2 , wherein the heavy chain polypeptide comprises a variable heavy region, a constant heavy region 1, a hinge region, a constant heavy region 2 and a constant heavy region 3.

15 . The method of claim 2 , wherein the light chain polypeptide comprises a variable light region and a constant light region.

16 . The method of claim 1 , wherein the recombinant nucleic acid sequence further comprises a Kozak sequence.

17 . The method of claim 1 , wherein the recombinant nucleic acid sequence further comprises an immunoglobulin (Ig) signal peptide.

18 . The method of claim 17 , wherein the Ig signal peptide comprises an IgE or IgG signal peptide.

19 . The method of claim 1 , wherein the recombinant nucleic acid sequence comprises a nucleic acid sequence encoding at least one amino acid sequence of SEQ ID NOs:1, 2, 5, 41, 43, 45, 46, 47, 48, 49, 51, 53, 55, 57, 59, and 61.

20 . The method of claim 1 , wherein the recombinant nucleic acid sequence comprises at least one nucleic acid sequence of SEQ ID NOs:3, 4, 6, 7, 40, 42, 44, 50, 52, 54, 56, 58, 60, 62 and 63.

21 . The method of claim 4 , wherein the first recombinant nucleic acid sequence is expressed in the subject to generate a first polypeptide and the second recombinant nucleic acid is expressed in the subject to generate a second polypeptide, wherein the synthetic antibody is generated by the first and second polypeptides.

22 . The method of claim 21 , wherein the first recombinant nucleic acid sequence further comprises a first promoter for expressing the first polypeptide in the subject and wherein the second recombinant nucleic acid sequence further comprises a second promoter for expressing the second polypeptide in the subject.

23 . The method of claim 22 , wherein the first promoter and second promoter are the same.

24 . The method of claim 23 , wherein the promoter is a cytomegalovirus (CMV) promoter.

25 . The method of claim 21 , wherein the heavy chain polypeptide comprises a variable heavy region and a constant heavy region 1.

26 . The method of claim 21 , wherein the heavy chain polypeptide comprises a variable heavy region, a constant heavy region 1, a hinge region, a constant heavy region 2 and a constant heavy region 3.

27 . The method of claim 21 , wherein the light chain polypeptide comprises a variable light region and a constant light region.

28 . The method of claim 21 , wherein the first recombinant nucleic acid sequence and the second recombinant nucleic acid sequence further comprise a Kozak sequence.

29 . The method of claim 21 , wherein the first recombinant nucleic acid sequence and the second recombinant nucleic acid sequence further comprise an immunoglobulin (Ig) signal peptide.

30 . The method of claim 29 , wherein the Ig signal peptide comprises an IgE or IgG signal peptide.

31 . A method of preventing or treating a disease in a subject, the method comprising generating a synthetic antibody in a subject according to the method of claim 1 .

32 . The method of claim 31 , wherein the synthetic antibody is specific for a foreign antigen.

33 . The method of claim 32 , wherein the foreign antigen is derived from a virus.

34 . The method of claim 33 , wherein the virus is Human immunodeficiency virus (HIV), Chikungunya virus (CHIKV) or Dengue virus.

35 . The method of claim 34 , wherein the virus is HIV.

36 . The method of claim 35 , wherein the recombinant nucleic acid sequence comprises a nucleic acid sequence encoding at least one amino acid sequence of SEQ ID NOs:1, 2, 5, 46, 47, 48, 49, 51, 53, 55, and 57.

37 . The method of claim 35 , wherein the recombinant nucleic acid sequence comprises at least one nucleic acid sequence of SEQ ID NOs:3, 4, 6, 7, 50, 52, 55, 56, 62, 63 and 64.

38 . The method of claim 34 , wherein the virus is CHIKV.

39 . The method of claim 38 , wherein the recombinant nucleic acid sequence comprises a nucleic acid sequence encoding at least one amino acid sequence of SEQ ID NOs:59 and 61.

40 . The method of claim 38 , wherein the recombinant nucleic acid s

Assignees

• Univ Pennsylvania

Inventors

• Weiner David B
• Muthumani Kar
• Sardesai Niranjan
• Flingai Seleeke

Classifications

• A61P31/18

  for HIV · CPC title

• A61P31/14

  for RNA viruses · CPC title

• C07K16/1145

  Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site · CPC title

• C07K16/116 Primary

  Togaviridae (F); Matonaviridae (F); Flaviviridae (F) · CPC title

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title